

CITATION REPORT

List of articles citing

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparison

DOI: 10.1007/s13300-018-0456-7
Diabetes Therapy, 2018, 9, 1491-1500.

Source: <https://exaly.com/paper-pdf/71193839/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. <i>Diabetes Therapy</i> , 2019 , 10, 2153-2167	3.6	12
8	Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. <i>Diabetes Research and Clinical Practice</i> , 2019 , 148, 222-233	7.4	1
7	Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes. <i>Journal of Comparative Effectiveness Research</i> , 2020 , 9, 781-794	2.1	6
6	Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 791-799	6.7	5
5	Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. <i>Cost Effectiveness and Resource Allocation</i> , 2021 , 19, 46	2.4	1
4	The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study. <i>Diabetes Mellitus</i> , 2019 , 22, 348-357	1.6	
3	Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. <i>Diabetes Therapy</i> , 2021 , 12, 3201-3215	3.6	1
2	Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients. 2022 ,		0
1	CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece. Volume 15, 97-109		0